although no objective responses have been observed in clinical trials (Kerr et al., 1987 (Kerr et al., , 1989 . The reasons for these discrepancies are unknown although differences in the mechanism of action of FAA between mouse and man may be significant. In murine tumour models, the action of FAA is characterised by the rapid shutdown of tumour vasculature, the appearance of haemorrhagic necrosis within 4 h of drug administration, and activity against advanced solid tumours that are normally resistant to conventional cytotoxic agents (Bibby et al., 1989a; Zwi et al., 1989) . One further characteristic of FAA induced responses is that activity is dependent upon the site of tumour implantation (Bibby et al., 1989b; Giavazzi et al., 1988) . Recent studies in this laboratory have demonstrated that murine colon tumours (MAC) grown subcutaneously respond to FAA (90% tumour inhibiton) whereas the same cells grown systemically (as small spheroid-like nodules in the lung) or intraperitoneally (as ascites) do not respond (Bibby et al., 1989b) . The reasons for these site dependent responses are unknown although differences in drug distribution between tumours with different histological characteristics and vascular supply may be a highly significant factor. The aim of this study therefore is to assess whether or not differences in FAA bioavailability can explain the spectrum of anti-tumour activity observed in the murine colon tumour model, MAC 15A. In addition, preliminary studies incorporating S-9 liver fractions or plasma from responding tumour bearing mice were conducted in vitro to further study the possibility of a cytotoxic metabolite being responsible for the anti-tumour activity of FAA as suggested by Chabot et al. (1989a).
The relationship between tissue levels of flavone acetic acid (NSC 37512) and site dependent anti-tumour activity in murine colon tumours Flavone acetic acid (2-phenyl-8-[carboxymethyl] -benzopyran-4-one NSC 347512) (FAA) is a compound that is capable of inducing significant responses in several murine solid tumours (Corbett et al., 1986; Plowman et al., 1986; Bibby et al., 1987b) although no objective responses have been observed in clinical trials (Kerr et al., 1987 (Kerr et al., , 1989 . The reasons for these discrepancies are unknown although differences in the mechanism of action of FAA between mouse and man may be significant. In murine tumour models, the action of FAA is characterised by the rapid shutdown of tumour vasculature, the appearance of haemorrhagic necrosis within 4 h of drug administration, and activity against advanced solid tumours that are normally resistant to conventional cytotoxic agents (Bibby et al., 1989a; Zwi et al., 1989) . One further characteristic of FAA induced responses is that activity is dependent upon the site of tumour implantation (Bibby et al., 1989b; Giavazzi et al., 1988) . Recent studies in this laboratory have demonstrated that murine colon tumours (MAC) grown subcutaneously respond to FAA (90% tumour inhibiton) whereas the same cells grown systemically (as small spheroid-like nodules in the lung) or intraperitoneally (as ascites) do not respond (Bibby et al., 1989b) . The reasons for these site dependent responses are unknown although differences in drug distribution between tumours with different histological characteristics and vascular supply may be a highly significant factor. The aim of this study therefore is to assess whether or not differences in FAA bioavailability can explain the spectrum of anti-tumour activity observed in the murine colon tumour model, MAC 15A. In addition, preliminary studies incorporating S-9 liver fractions or plasma from responding tumour bearing mice were conducted in vitro to further study the possibility of a cytotoxic metabolite being responsible for the anti-tumour activity of FAA as suggested by Chabot et al. (1989a) .
Materials and methods

Animals
Pure strain NMRI mice (6-8 weeks of age) were used from our inbred colony. They received CRM diet (Labsure, Croydon, England) and water ad libitum.
Test compounds Clinically formulated FAA was a gift from Lipha (Lyon, France). It was dissolved in physiological saline at an appropriate concentration for a desired dose to be administered in 0.1 ml per 10 g body weight.
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Tumour system
The development of several adenocarcinomas of the large bowel in NMRI mice from primary tumours induced by prolonged administration of 1-2-dimethylhydrazine has been described previously (Double et al., 1975 , Bibby et al., 1987a FAA was measured by reverse phase HPLC, details of which have been published elsewhere (Kerr et al., 1985; Double et al., 1986) . Standard curves were prepared by the addition of FAA to buffered control mouse plasma (pH 4.0) and plotting the ratio of peak area of FAA to internal standard against drug concentration. The assay was sensitive to drug concentrations down to 10ngml-'.
Pharmacokinetic parameter determination All pharmacokinetic parameters were calculated using standard formulae (Gibaldi, 1984) . The terminal half life (t1) was calculated by least square linear regression analysis of the terminal log linear phase of the curve and the elimination constant (KeI) determined from the relationship Kei = 0.693/ t4. The area under the curve (AUC) from time 0 to the last measured time point (tj) was calculated using the trapezoid rule. The remaining area from t, to co was calculated using the equation Cz/Kel where C, equals the concentration at t,. Total body clearance (CIT) was calculated as dose/AUC. Volume of distribution was calculated as dose/C0 where C0 is the concentration at time 0.
Results FAA was administered to tumour bearing and non-tumour bearing mice at 200 mg kg-' ip, and the resulting plasma and tissue concentrations of FAA at various times thereafter are presented in Figures 1 and 2 . In all cases the elimination of FAA was biphasic. The presence of MAC 1 5A tumours grown iv or sc has a significant effect upon the pharmacokinetic behaviour of FAA compared to non-tumour bearing mice. In both MAC 15A iv and sc tumour bearing mice the total body clearance of FAA is reduced in all tissues compared with non tumour bearing mice resulting in significant E C, Plasma protein binding Protein binding of FAA in plasma of non-tumour bearing and MAC 1 5A bearing mice was examined at 15 min and 8 h after FAA administration. Plasma samples were divided into two aliquots, one of which was extracted and analysed as described above the other being added to a Centrifreem micropartition system (Amicon). Following centrifugation at 200 g for 20 min the ultrafiltrate was collected and FAA was extracted and analysed as described above.
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Preparation of S-9 liver fractions and chemosensitivity studies in vitro S-9 microsomes were prepared from normal and phenobarbitone pre-treated mice (60 mg kg' ip for 4 days) by the methods described by Chabot et al. (1989a) . Mice were sacrificed by cervical dislocation and livers were aseptically excised and gently homogenised in four times their weight of cold RPMI 1640 tissue culture medium (pH 7.4) using a motor driven teflon/glass homogeniser and centrifuged at 9,000 g for 20 min at 4°C. One ml of this supernatent was added to a sterile universal tube containing 3 ml of MAC 15A cells in suspension. To this 0.5 ml FAA (1-5 mg ml-') and 0.5 ml of co-factors (glucose-6-phosphate, 33 mg ml-' NADP, 4 mg ml-'; MgCI2.6H20, 6.6 mg ml-' and glucose-6-phosphate dehydrogenase, 1.66 units) were added and incubated at 37°C for 1 h. Following drug exposure, cytotoxic effects were assessed using a clonogenic assay, the details of which have been published elsewhere (Phillips et al., 1988) . All assays were performed in triplicate and cells in the expontial phase of growth were used throughout. Controls containing S-9 preparations and co-factors were used as well as a positive control assay using cyclophosphamide (0.5 to 2 mg ml-' for 1 h). Influence of FAA containing mouse plamsa on cytotoxicity in vitro Blood samples from normal mice and mice bearing subcutaneous MAC 1 5A tumours were collected by cardiac puncture I h and 4 h after the ip administration of a therapeutic dose of FAA (200 mg kg-'). Blood was immediately centrifuged and plasma samples (1 ml) added directly to a pellet of MAC 15A cells and incubated at 3TC for 1 h. Following exposure to plasma samples the cells were washed and chemosensitivity was assessed as described previously. For control cultures FAA, at peak plasma drug concentrations (0.6 mg ml-') was added to fresh mouse plasma. (Table I ). The increase in plasma AUC>0 values in MAC 15A iv and sc tumour bearing mice relative to non-tumour bearing mice (AUCTB/AUCNTB = 2.4 and 2.6 respectively, TB = tumour bearing, NTB = non tumour bearing) is not accompanied by an increase in peak plasma drug concentrations (PeakTB/PeakNTB = 0.91 and 1.12 respectively, Table II (Bibby et al., 1987b; Bibby et al., 1988; Bibby et al., 1989a) . There is a poor correlation between pharmacokinetic parameters at the tumour site and the final outcome of chemotherapy in vivo. In both the resistant MAC 15A ip and iv tumour lines AUC and peak levels of FAA are higher than these achieved in the very responsive MAC 16 tumour (Table III) . Plasma protein binding of FAA is presented in Table IV . There are no significant differences in plasma protein binding between non-tumour and MAC 15A iv and sc tumour bearing mice with values ranging from 68.7% to 85.6%.
The cytotoxic activity of FAA in vitro was not enhanced by the inclusion of S-9 or phenobarbitone induced S-9 liver fractions in the incubation mixture (Figure 3) plasma protein binding (Table IV) . It also seems unlikely that this phenomenon is a direct result of the dose dependent, non-linear characteristic of FAA pharmacokinetics Chabot et al., 1989b) as the increase in plasma AUC-,0 in tumour bearing mice is not accompanied by an increase in peak concentrations (Table II) (Donelli et al., 1984) . Whatever the mechanism, the relevance of these changes to anti-tumour activity appear to be limited, as increases in plasma and tissue AUC&, values for FAA occur in both the resistant MAC 15A iv and the sensitive MAC 15A sc models (Table I ). In addition, such significant increases in plasma and tissue AUC values for FAA were not observed in MAC 26 and MAC 16 tumours, both of which are sensitive to FAA (Cummings et al., 1989; Bibby et al., 1988) . In terms of tolerance however, these observations may be relevant particularly as Zaharko et al. (1986) Kerr et al., 1987) .
Two metabolites of FAA were detected in vivo. The first metabolite eluted was present at low levels (7% of circulating FAA) in plasma samples but was barely detectable in other tissues. Similar findings have been reported in NMRI mice (Cummings et al., 1989) and Balb/c mice . The second metabolite could only be detected in liver samples. Attempts to identify cytotoxic metabolites in vivo or to activate FAA to a cytotoxic species in vitro failed to substantiate the results presented by Chabot et al. (1989a) . In this and previous studies , no metabolites arising from the inclusion of S-9 liver fractions in the incubation 'mix' in vitro were detected by HPLC. Furthermore, as no metabolites could be detected in tumour tissues, their role in the anti-tumour activity of FAA remains questionable.
In conclusion, the results of this study have demonstrated that the site dependent activity of FAA cannot be fully explained on the basis of differences in drug and/or metabolite bioavailability or on altered pharmacokinetic profiles caused by the presence of large tumour loads. The reasons for the site dependent activity of FAA remain unclear although it is likely that the activity of FAA against sc tumours relies in part on the specific vascular feature of tumours at this site.
